This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Cancer or Melanoma
and you are
between 18 and 66
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

Background: - One possible treatment for advanced melanoma involves collecting white blood cells from the person with cancer and growing them in a laboratory. The cells can then be given back to the donor. This study will use this white blood cell treatment with the cancer treatment drug vemurafenib. Vemurafenib targets melanoma cells that have a mutation in the B-raf gene, and may be able to make them shrink. Objectives: - To see if vemurafenib and white blood cell therapy is a safe and effective treatment for advanced melanoma. Eligibility: - Individuals at least 18 years and less than or equal to 66 years of age who have advanced melanoma that contains the B-raf genetic mutation. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. - White blood cells will be collected from tumor cells. These cells will be collected during surgery or a tumor biopsy. - Participants will have leukapheresis to collect additional white blood cells for the procedure. - Participants will take vemurafenib twice a day, starting 3 weeks before receiving the white blood cells. - Participants will have 1 week of chemotherapy to prepare their immune system to accept the white blood cells. - Participants will receive an infusion of their collected white blood cells. They will also receive aldesleukin for up to 5 days to boost the immune system s response to the white blood cells. They will remain in the hospital until they have recovered from the treatment. - Participants will have frequent follow-up visits to monitor the outcome of the treatment.

Provided treatments

  • Drug: Vemurafenib
  • Biological: Young TIL
  • Drug: Cyclophosphamide
  • Drug: Fludarabine
  • Drug: Aldesleukin

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01585415. The sponsor of the trial is National Cancer Institute (NCI) and it is looking for 12 volunteers for the current phase.
Official trial title:
A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma